RxDoctor Payments Data

Raphaele Alaura, APRN

Nurse Practitioner · Las Vegas, NVNPI 1821693037

Payments from drug & device makers

$5,409in general payments, 2019–2025

Across 173 payments — averaging $31.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Amgen$677
  • Daiichi Sankyo Inc.$410
  • Lilly USA, LLC$329
  • Bristol Myers Squibb$195
  • Seagen Inc.$141
  • plus $2K from 32 others

What the payments were for

  • Speaking & faculty fees$56010%
  • Food & beverage$3,01156%
  • Education$55810%
  • Other$1,28024%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,409 in reported general payments places this provider in the 90th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$103,812
Medicare patients
461
Services billed
4,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$31,682
Exemestane13$689
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen16$332
Potassium Chloride11$296
Anastrozole11$207
Gabapentin17$203
Levothyroxine Sodium22$167
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine11$166
Amlodipine Besylate33$132
Atorvastatin Calcium31$125
Losartan Potassium19$115
Methylprednisolone22$110
Omeprazole13$100
Metoprolol Tartrate18$77
Prednisone14$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$106$31,68226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →